Sharon Fekrat, MD, FACS, FASRS contributed her expertise to a recent Viewpoints panel featured in the Ophthalmology Times article, “8 things to know about aflibercept 8 mg for retinal vascular disease.”
The piece highlights the growing clinical impact of aflibercept 8 mg (EYLEA HD), which offers faster drying, longer durability, and the potential for fewer injections while maintaining treatment goals for conditions such as AMD, DME, and RVO. The FDA recently expanded its approval of the 8 mg dose to include macular edema following retinal vein occlusion, with flexible dosing options that may reduce burden for both patients and clinics.
Dr. Fekrat joined two other retina specialists to discuss how next‑generation anti‑VEGF therapies are shaping individualized care and improving outcomes for patients with retinal vascular disease.